- Lung Cancer Basics
October 6-7, 2017
The Washington Court Hotel
525 New Jersey Ave NW
Washington, DC 20001
Join other healthcare professionals to learn best practices and lessons learned in lung cancer screening and care programs across the US!
Registration is now open. Please register by clicking here.
Click here to view the draft event agenda.
|Registration Type||Screening Center of Excellence||Non-Screening Center of Excellence|
|Early registration (May 1 – June 15)||$175||$250|
|Regular registration (June 16 – August 15)||$200||$275|
|Late registration (August 15 - September 25)||$275||$350|
The refund deadline is September 15. A refund will be given, less a $35 processing fee.
The hotel room rate is $149 single/$169 double plus taxes. The room block will close August 31 and these rates cannot be guaranteed after that date. You will receive reservation information with your registration confirmation letter.
The Third Annual Lung Cancer Alliance Collaborating for Improved Screening and Care Conference will bring together healthcare professionals from lung cancer screening and care programs across the country to meet, share lessons learned, troubleshoot problems and identify continued areas of need in lung cancer screening programs. This conference is designed for healthcare professionals – including nurses, nurse navigators, PAs, physicians and other clinical and administrative support staff involved directly in lung cancer screening and treatment programs.
The target audience for this event are physicians, nurses, social workers, and other health care professionals (including administrators) who work directly in providing the service of lung cancer screening and treatment. This includes peripheral activities such as the provision of referrals to screening, smoking cessation services, and follow up care.
After completion of this activity, participants will be able to:
1. Create a strategy to improve workflow and outcomes in a lung cancer screening program
2. Create a comprehensive patient education strategy for those at high risk for lung cancer
3. Identify at least three program elements to increase appropriate provider referral
4. Describe appropriate molecular testing in early detection of lung cancer and corresponding treatments
This activity is jointly provided by Global Education Group and Lung Cancer Alliance.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Lung Cancer Alliance. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this live activity for a maximum of 8.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 8.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Instructions for Obtaining Credit
In order to receive credit, participants must complete the online evaluation and application at the end of the end of the event. Statements of credit will be mailed within 4 to 6 weeks following the program.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Lung Cancer Alliance do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.